FDA grants HDE marketing approval for BSD-2000 Hyperthermia System to treat cervical cancer
March 11, 2017
In 2010, an estimated 12,200 women in the United States were diagnosed with cervical cancer, and an estimated 4,210 died of the disease. It is estimated that approximately $1.4 billion is spent in the U.S. each year on cervical cancer treatment. Cervical cancer is the fifth most common cancer in women worldwide and the leading cause of death from cancer among women in developing countries. Researchers have predicted that developing countries could face a 75% increase in the number of cervical cancer cases in the next two decades due to growth and aging of the population.
The BSD-2000 Hyperthermia System - developed and patented exclusively by BSD - delivers localized therapeutic heating (hyperthermia) to solid tumors by applying radiofrequency (RF) energy. The BSD-2000 creates a central focusing of energy that can be electronically focused to target the shape, size, and location of the tumor, thus providing dynamic control of the heating delivered to the tumor region. This method of therapeutic heating utilizes the adjustment of frequency, phase, and amplitude from multiple power sources, along with applicator selection and patient positioning, to optimize the deposition of heating energy into the targeted body tissues.
Source BSD Medical Corporation